Ti Zhang

机构：Shenzhen Nanshan Center for Chronic Disease Control · ORCID：0000-0002-8759-4395

发表论文 237 篇 · 总被引 7905 次 · h-index 41

代表论文

• GPR37 promotes colorectal cancer liver metastases by enhancing the glycolysis and histone lactylation via Hippo pathway (2023 · Oncogene · 被引 122)
• China Liver Cancer Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2024 Edition) (2025 · Liver Cancer · 被引 41)
• Tyrosine Kinase Inhibitors Plus Anti-PD-1 Antibodies with Hepatic Arterial Infusion Chemotherapy or Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma (2023 · Journal of Hepatocellular Carcinoma · 被引 16)
• Hepatectomy After Conversion Therapy with Hepatic Arterial Infusion Chemotherapy, Tyrosine Kinase Inhibitors and Anti-PD-1 Antibodies for Initially Unresectable Hepatocellular Carcinoma (2023 · Journal of Hepatocellular Carcinoma · 被引 14)
• GPR37 promotes colorectal cancer against ferroptosis by reprogramming lipid metabolism via p38-SCD1 axis (2024 · APOPTOSIS · 被引 12)
• Risk factors for acute kidney injury and kidney relapse in patients with lupus podocytopathy (2024 · Clinical Kidney Journal · 被引 9)